Status:
UNKNOWN
Triamcinolone Acetonide as an Adjunctive to VPDT in ARMD.
Lead Sponsor:
Canadian Retinal Trials Group
Collaborating Sponsors:
University of British Columbia
QLT Inc.
Conditions:
Age-Related Macular Degeneration
Eligibility:
All Genders
50+ years
Phase:
PHASE2
PHASE3
Brief Summary
A 24 - month Study looking at the the changes in visual acuity of patients receiving PDT therapy in conjunction with intravitreal triamcinolone.
Detailed Description
This study will evaluate the effect of Triamcinolone Acetonide in conjunction with photodynamic therapy for the treatment of sub-foveal choroidal neovascular membranes secondary to age-related macular...
Eligibility Criteria
Inclusion
- Individuals with predominantly classic, subfoveal CNV secondary to AMD.
- No previous PDT Treatment in study eye.
Exclusion
- CNV from conditions, other than AMD.
- Other disease that could be responsible for decreased vision.
Key Trial Info
Start Date :
January 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
March 1 2008
Estimated Enrollment :
120 Patients enrolled
Trial Details
Trial ID
NCT00148551
Start Date
January 1 2004
End Date
March 1 2008
Last Update
July 30 2007
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Eye Care Centre
Vancouver, British Columbia, Canada